Eupraxia Pharmaceuticals Reports Third Quarter 2022 Financial Results

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug...

Related Keywords

Czech Republic ,Canada ,United Kingdom ,Denmark ,Poland ,British ,Canadian ,Vik Peck ,Paul Brennan ,James Helliwell ,Adam Peeler ,Life Sciences Company Of The Year Award ,International Financial Reporting Standards ,Eupraxia Pharmaceuticals Inc ,Company Phase ,Eupraxia Audit Committee ,Life Sciences British Columbia ,Orphan Drug ,Chief Business Officer ,Financial Highlights ,Emerging Life Sciences Company ,Year Award ,Life Sciences British ,Chief Business ,Data Safety Monitoring Board ,Magnetic Resonance Imaging ,Management Discussion ,Audit Committee ,Regarding Forward Looking Statements ,Although Eupraxia ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Earnings ,